Skip to content

Huysse MedConsult

Active Private limited companyfounded 2021active for 4 yearsKoutemstraat 34, 3370 BoutersemKBO/BCE: BE 0778.801.122

Lifetime

4 annual accounts with figures on one time axis
peak of €94,326 in 2022
€81,892▲ €82,519
lowest -€13,290 in 2023
€66,389▲ €68,085
peak of €75,998 in 2022
€51,601▼ 14.3%
€93,168▲ 830%
Board1 name since 2021
1 director
Documentsfilings and deeds
04-12-202558 days before the deadline
2025micro format
Gross margin from -€627 to €81,892Profit of €66,389, after a lossDividend €75,000Equity from €60,212 to €51,601Debts from €10,014 to €93,168Cash from €11,919 to €123,120

Key points

from the 2025 annual accounts

Equity

€51,601 ▼ 14.3%
60,2122024+66,389Profit-75,000Dividend51,6012025

Huysse MedConsult paid out €75,000 in dividends. That is 113% of the 2025 profit.

Result

€66,389 €66,389
-€1,7002024€66,4002025

Back in profit in 2025, after a loss of €1,696 in 2024.

Turnover

≈ €240,000 estimated

The micro format states no turnover.

Liquidity

1.57 was 6.88 in 2024

Short-term debts rose from €10,014 to €91,593.

Filings

4 annual accounts since 2022
deadline2022202320242025

The last four annual accounts were filed 56 to 65 days before the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 39,329 companies had the same profile as Huysse MedConsult has now. Each dot stands for 99 companies, two years later.

95.7%
were still trading
2.4%
stopped another way
1.8%
went bankrupt
  • Micro
  • 2 to 5 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 39,329 companies, not a prediction for Huysse MedConsult. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 17-12-2021
  • 20 sharesdeed of 21-12-2021
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0778801122
Incorporation Founding capital of €2,000, 20 shares · Founded by · appointed as statutory director · published on 21-12-2021 · Gazette deed
First establishment Koutemstraat 34, Boutersem
All 10 events

Comparable companies

same main activity, similar in size and age
Company
Huysse MedConsult Boutersem €144,769 €81,892 35.6% -
DILMA CONSULT Overijse €127,819 €145,578 2.3% -
OPERO Grimbergen €225,981 €168,579 2.2% -
MDC Kestens Lille €140,827 €60,103 98.2% -
GMPharm Perwez €215,626 €73,251 81.2% -
JESSAV Oosterzele €136,083 €88,416 1.9% -
LP ENGINEERING Liège €138,903 €53,690 89.6% -

These companies have the same main activity as Huysse MedConsult: research and development on biotechnology (NACE 72101). They are comparable in size and age: total assets between €128,000 and €226,000, founded between 2020 and 2022.

Official details

Source: KBO
Status
Active since 17-12-2021Normal situation
Activity
Research and development on biotechnologyNACE 72101and 1 other
Establishment unit
2.325.976.6583370 Boutersem, since 17-12-2021
Financial year end
30 June
Peppol
Reachable since 30-01-2025
Company details

Annual accounts to 30-06-2025

€144,769▲ 106%
Filing
Filed on 04-12-2025, 58 days before the end of the filing period
Financials

Insights on Huysse MedConsult

Huysse MedConsult files the micro format. That format states no turnover. The gross margin fell from €94,326 in 2022 to €81,892 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about Huysse MedConsult

What is the company number of Huysse MedConsult?
The company number of Huysse MedConsult is 0778.801.122. The VAT number is the same number with BE in front: BE 0778.801.122.
Where is Huysse MedConsult based?
The registered office is at Koutemstraat 34, 3370 Boutersem.Company details
What does Huysse MedConsult do?
According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
What is the legal form of Huysse MedConsult?
Huysse MedConsult is a private limited company (BV).
When was Huysse MedConsult founded?
Huysse MedConsult was founded on 17-12-2021.
Is Huysse MedConsult still active?
Yes, Huysse MedConsult is an active enterprise in the KBO register.
What is the turnover of Huysse MedConsult?
The turnover in financial year 2025 is ≈ €240,000. This figure is estimated from the gross margin of €81,892 and 2,981 comparable companies of the same size. It probably lies between €160,000 and €420,000. It is a rough estimate.Financials
Is Huysse MedConsult profitable?
In financial year 2025, Huysse MedConsult made a profit of €66,389.
Where can I find the annual accounts of Huysse MedConsult?
Huysse MedConsult filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Huysse MedConsult due?
Huysse MedConsult must file the annual accounts for financial year 2026 by 31-01-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.